Finance

Lists
002773:SHE
Chengdu Kanghong Pharma Grp Co Ltd
CN¥20,15
-0,25%
(-0,050) 1D
14 Okt., 13:14:33 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002773...
Open
CN¥20,02
High
CN¥20,35
Low
CN¥19,93
Mkt. cap
18,55 mjd
Avg. vol.
7,42 m
Volume
3,74 m
Dividend
3,47%
Quarterly dividend
CN¥0,17
Ex-dividend date
09 Jun. 2026
P/E ratio
18,66
52-wk high
CN¥36,10
52-wk low
CN¥18,62
EPS
CN¥1,08
Shares outstanding
921,33 m
No. of employees
4 k
Open
CN¥20,02
High
CN¥20,35
Low
CN¥19,93
Mkt. cap
18,55 mjd
Avg. vol.
7,42 m
Volume
3,74 m
Dividend
3,47%
Quarterly dividend
CN¥0,17
Ex-dividend date
09 Jun. 2026
P/E ratio
18,66
52-wk high
CN¥36,10
52-wk low
CN¥18,62
EPS
CN¥1,08
Shares outstanding
921,33 m
No. of employees
4 k
News stories
From web sources and news partners
Profile
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, central nervous, digestive and endocrine systems. The company is listed on the Shenzhen stock exchange with a market capitalization at around $6 billion. As of May 2021, the company had 18 drugs on the market including Lumitin. Additional products include Songling xuemaikang capsules, Keluoxin capsules, Xinluona, Bolexin and Bosiqing, Yitaning, Shugan Jieyu, Danshu, and Yiqing. Kanghong also currently has 13 subsidiaries in China, Israel, and the United States. Wikipedia
About Chengdu Kanghong Pharma Grp Co Ltd
CEO-
Employees4,47 k
Founded03 Okt. 1996
Headquarters-
SectorPharmaceutical industry
Websitecnkh.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,17 mjd
961,27 m
1,05 mjd
1,13 mjd
Cost of goods sold
103,16 m
116,91 m
118,65 m
132,03 m
Cost of revenue
103,16 m
116,91 m
118,65 m
132,03 m
Research and development expenses
119,54 m
198,94 m
86,77 m
138,57 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
595,28 m
521,75 m
478,88 m
554,55 m
Operating expense
697,02 m
764,40 m
582,81 m
717,78 m
Total operating expenses
800,18 m
881,31 m
701,46 m
849,80 m
Operating income
370,02 m
79,96 m
345,02 m
282,88 m
Other non operating income
-19,53 m
19,27 m
-1,04 m
-1,54 m
EBT including unusual items
355,99 m
147,66 m
358,51 m
301,88 m
EBT excluding unusual items
364,66 m
135,96 m
356,39 m
306,28 m
Income tax expense
56,73 m
23,28 m
55,31 m
50,13 m
Effective tax rate
15,94%
15,77%
15,43%
16,61%
Other operating expenses
-17,83 m
43,89 m
16,62 m
23,18 m
Net income
303,21 m
130,06 m
307,48 m
257,26 m
Net profit margin
25,91%
13,53%
29,38%
22,71%
Earnings per share
-
-
-
-
Interest and investment income
14,20 m
36,91 m
12,63 m
24,92 m
Interest expense
-
-
-
-
Net interest expenses
14,20 m
36,91 m
12,63 m
24,92 m
Depreciation and amortization charges
-
-
-
-
EBITDA
427,31 m
139,05 m
404,11 m
345,15 m
Gain or loss from assets sale
3,47 k
-9,78 k
-
61,06 k
AI content may include mistakes. Learn more
Google-programme